SynthesisJournal of the American Heart Association2025

Safety and Efficacy of Mavacamten and Aficamten in Patients With Hypertrophic Cardiomyopathy.

Bryton J Davis et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.